Clinical trial · Observational
Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain
Intrathecal Targeted Drug Delivery for Cancer Associated Pain
NCT05674240CI-TRIAL-00106662completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Associated Pain | — | UNRESOLVED | — |
| Cancer Pain | — | UNRESOLVED | — |
| Chronic Pain | — | UNRESOLVED | — |
| Neuropathic Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conservative medical management | Combination Product | — | UNRESOLVED |
| Intrathecal Targeted Drug Delivery | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cancer associated pain treated with conservative medical management (CMM) only
- description
- Subjects in this group are patients who opted for conservative medical management for their chronic pain that is cancer associated, including physical therapy, oral or transdermal medications and injections
- interventionNames
- Combination Product: Conservative medical management
- label
- Cancer associated pain treated with Intrathecal Drug Delivery system (IDDs) along with CMM
- description
- Patients in this group are those that opted for targeted drug delivery along with conservative medical management of their cancer-associated pain
- interventionNames
- Device: Intrathecal Targeted Drug Delivery
- Combination Product: Conservative medical management
Primary outcomes (2)
- measure
- Change in Pain Intensity from Screening through 3-Months
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Age of 21 and older * Uncontrolled cancer-associated pain (pain score of \>5 on NRS) despite oral use of 60 mg/d morphine equivalent a week prior to screening * Adverse side effects from long term opioid use defined as limiting or severely affecting patient's day to day function * Life expectancy of \> 3 months Exclusion Criteria: * Active infections * Controlled pain without adverse side effects that are limiting day to day function * Mechanical barriers * Obstruction of Cerebrospinal Fluid (CSF)
References
Publications (0)
Data not yet available
No reference posted for this study.